source
- Roche cans one Carmot obesity asset as another shows best-in-class potentialAcmopatide met the main goal of a Phase 2 study in type 1 diabetes, but Roche is axing the investigational drug to prioritize enicepatide for weight loss, type 2 diabetes and cardiovascular outcome…BioSpace · 6d ago↗ source
- STAT+: Merck strikes voluntary licensing deals in poor countries for an experimental HIV prevention pillMerck is striking licensing deals for its experimental HIV prevention pill in hope of getting wide-scale production started quickly.STAT · 6d ago↗ source
- Merck stages expanded access to monthly HIV PrEP pill ahead of approvalFollowing in the footsteps of Gilead, Merck has signed voluntary licensing agreements to enable access to its investigational HIV PrEP pill alimatravir ahead of any regulatory submissions.